• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Liquidia Corporation (Amendment)

    12/14/23 4:40:34 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    SC 13D/A 1 p23-2975sc13da.htm LIQUIDIA CORPORATION

     

    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Liquidia Corporation

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    53635D202

    (CUSIP Number)
     
    David Johnson
    Caligan Partners LP
    590 Madison Avenue
    New York, NY 10022
    (646) 859-8204
     
    Eleazer Klein, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    December 14, 2023

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

     

    (Page 1 of 7 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 53635D202SCHEDULE 13D/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Caligan Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    10,360,945 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    10,360,945 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,360,945 shares of Common Stock

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    15.1%

    14

    TYPE OF REPORTING PERSON

    IA, PN

             

     

     

    CUSIP No. 53635D202SCHEDULE 13D/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    David Johnson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b)x
    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    106,132 shares of Common Stock underlying director stock options

    8

    SHARED VOTING POWER

    10,360,945 shares of Common Stock

    9

    SOLE DISPOSITIVE POWER

    106,132 shares of Common Stock underlying director stock options

    10

    SHARED DISPOSITIVE POWER

    10,360,945 shares of Common Stock

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    10,360,945 shares of Common Stock

    106,132 shares of Common Stock underlying director stock options

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    15.3%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 53635D202SCHEDULE 13D/APage 4 of 7 Pages

     

     

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2"). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
       
      Item 3 of the Schedule 13D is hereby amended and restated as follows:
       
      The Reporting Persons used a total of approximately $36,832,728 (including brokerage commissions) to acquire the Common Stock reported herein.  The source of the funds used to acquire the Common Stock reported herein was the working capital of the Caligan Fund.  The director stock options reported herein were acquired by Mr. Johnson for his services rendered to the Issuer as a member of the Issuer's board of directors.

     

    Item 4. PURPOSE OF TRANSACTION
       
      Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following:
       
      On December 14, 2023, funds managed by Caligan acquired 1,117,318 shares (“Offering Shares”) of Common Stock at a price of $7.16 per Offering Share upon the completion of  the Issuer’s public offering of shares of Common Stock pursuant to the Issuer's Prospectus (the “Prospectus”), filed pursuant to Rule 424(b)(2) with the Securities and Exchange Commission (the “SEC”) on December 12, 2023 (the “Offering”).
       
      In connection with the Offering, Caligan and Mr. Johnson each entered into a lock-up agreement (collectively, the "Offering Lock-Up Agreement") with the underwriters of the Offering that restrict their ability to sell or transfer their shares of Common Stock or any securities convertible into or exchangeable or exercisable for shares of Common Stock for a period of not less than 90 days after the date of the Prospectus (as defined in the underwriting agreement entered into by the Issuer in connection with the Offering) without the prior written consent of the representatives of the underwriters that participated in the Offering, subject to certain exceptions.
       
      The foregoing summary of the Offering Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Offering Lock-Up Agreement. A copy of the form of the Offering Lock-Up Agreement is attached hereto as Exhibit F and is incorporated herein by reference.

     

     

    CUSIP No. 53635D202SCHEDULE 13D/APage 5 of 7 Pages

     

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
      Items 5 (a)-(c) of the Schedule 13D is hereby amended and restated as follows:
       
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of and percentages of the shares of Common Stock beneficially owned by each Reporting Person.  The percentages set forth in this Schedule 13D are based upon 68,390,915 shares of Common Stock, as reported in the Issuer's Prospectus, after giving effect to the completion of the Offering, as described in the Prospectus, and assumes the exercise of the director stock options granted to Mr. Johnson.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Other than as disclosed in Items 4 and 6, no transactions in the Common Stock were effectuated by the Reporting Persons during the past sixty (60) days.
       

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
      Item 6 of the Schedule 13D is hereby amended and supplanted by the addition of the following:
       
      The Reporting Person's response to Item 4 in this Amendment No. 2 is incorporated by reference into this Item 6.
       
      Mr. Johnson has received and currently holds 106,132 nonstatutory director stock options exercisable (subject to vesting conditions) for 106,132 shares of Common Stock. Mr. Johnson is deemed to hold the securities for the benefit of funds and accounts managed by Caligan.
       

     

     

    CUSIP No. 53635D202SCHEDULE 13D/APage 6 of 7 Pages

     

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS

     

    Exhibit F: Form of Lock-Up Agreement (incorporated by reference to Form of Lock-Up Agreement filed as an exhibit to the Underwriting Agreement, filed as Exhibit 1.1 of the Form 8-K, filed by the Issuer on December 14, 2023).
       

     

     

    CUSIP No. 53635D202SCHEDULE 13D/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: December 14, 2023

      CALIGAN PARTNERS LP
         
         
      By: /s/ David Johnson
      Name:   David Johnson
      Title: Managing Partner
       
       
      /s/ David Johnson
      DAVID JOHNSON
       

     

     

     

     

    Get the next $LQDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    1/5/2024$18.00 → $28.00Buy
    Needham
    9/19/2022$3.00Underperform
    Wedbush
    9/1/2022$3.00Neutral → Underperform
    Wedbush
    More analyst ratings

    $LQDA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Liquidia Corporation

      10-Q - Liquidia Corp (0001819576) (Filer)

      5/8/25 7:00:23 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:40:47 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:05:36 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

      Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

      11/18/21 2:49:33 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Liquidia Technologies with a new price target

      Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

      12/20/24 7:42:58 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Liquidia Technologies

      Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Technologies upgraded by Raymond James

      Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy

      8/19/24 12:03:58 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will

      5/8/25 6:30:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

      MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company's Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-pre

      5/6/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

      Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia's amendment to its New Drug Application (NDA) for YUTREPIA™ (t

      5/2/25 5:28:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Adair Jason sold $6,479 worth of shares (455 units at $14.24), decreasing direct ownership by 0.25% to 183,849 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/30/25 4:15:23 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Saggar Rajeev sold $33,492 worth of shares (2,450 units at $13.67), decreasing direct ownership by 0.92% to 263,152 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/23/25 4:15:13 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Schundler Russell sold $80,931 worth of shares (5,964 units at $13.57), decreasing direct ownership by 1% to 570,301 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:06:09 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

      GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

      10/2/23 7:00:00 AM ET
      $EBS
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

      7/21/22 4:30:00 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Financials

    Live finance-specific insights

    See more
    • Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

      MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

      5/1/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024

      MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora

      11/4/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

      MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

      7/31/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/16/24 4:05:20 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/4/24 5:51:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      12/18/23 5:02:01 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      11/12/24 5:35:19 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      9/12/24 4:22:57 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      9/4/24 5:51:42 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care